Readoutin 103d
Janssen-Cilag Ltd. — Guselkumab
Phase 3 primary completion: A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Fistulizing Crohns Disease
Readoutin 103d
Phase 3 primary completion: A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.